Independent information services
Guides, comparisons, and research summaries for people trying to understand ibogaine and PTSD without mistaking early findings for established treatment guidance.
Context, uncertainty, safety, and legal limits
A clear starting point
Bright Basin 95 is an independent resource on ibogaine, PTSD, evidence, risks, and legality. The material is designed for veterans, families, and clinicians-in-training who need careful context before drawing conclusions. For the broader framing behind this work, start with our overview of ibogaine and PTSD evidence.
PTSD is a recognized mental health condition with established diagnostic and treatment guidance; the National Institute of Mental Health description of PTSD helps place emerging discussions in that wider clinical context. Our approach and boundaries are explained in the resource’s mission and principles.
What we provide
These are informational offerings: structured ways to review research language, compare sources, and keep safety and legal context visible. They are not medical, clinical, or treatment services.
Plain-language summaries separate study design, reported outcomes, and unanswered questions. When terminology appears, the ibogaine HCl information reference can help readers identify the compound being discussed without turning a research summary into a recommendation.
Our frameworks foreground evidence quality, individual risk factors, and the difference between interest and action. They also point readers toward questions raised by ibogaine treatment information in the United States, where legal and medical context matters.
Comparison material examines how claims, regulations, and treatment settings can differ. Readers weighing cross-border information may encounter treatment-center context in Mexico alongside discussion of Canadian ibogaine treatment-center listings; neither is a substitute for individualized medical advice.
Definitions and frequently asked questions make technical language more legible while preserving uncertainty. They include practical context around cost considerations for ibogaine treatment in Mexico and the limits of comparing services across jurisdictions.
How the material is organized
Research summaries should be read with attention to who was studied, what was measured, how long follow-up lasted, and what comparison was used. That matters especially when early, observational, or self-reported findings are interpreted as stronger proof than they are.
Ibogaine is commonly discussed in relation to several conditions, including in pages about ibogaine treatment claims for Parkinson’s disease. A comparison across topics can be useful precisely because it shows why a claim in one setting does not establish effectiveness or safety in another.
Legal context also belongs in the reading process. In the United States, ibogaine is listed as a Schedule I controlled substance under the DEA drug scheduling framework, a fact that shapes research, access, and the limits of public claims.
Frequently asked questions
Early findings can be worth understanding without being treated as settled guidance.
Keep the frame intact
Bright Basin 95 brings together research summaries, comparisons, glossary material, and FAQ context so readers can approach ibogaine and PTSD claims with care. It does not replace medical or legal counsel, and it does not offer treatment.